Search

Displaying results 2241 - 2250 of 4301 in total
  1. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

  2. Drug

    Samarium (153Sm) lexidronam

    go.drugbank.com/drugs/DB05273
    Approved

    Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. … Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help

  3. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … Hereditary transthyretin amyloidosis is caused by single-nucleotide variants in the gene encoding transthyretin (TTR), which lead to transthyretin misfolding and the deposition of amyloid substance systemically

  4. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S.

  5. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.

  6. Drug

    Tovorafenib

    go.drugbank.com/drugs/DB15266
    ApprovedInvestigational

    [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.

  7. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate)

  8. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.

  9. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … [A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling

  10. Drug

    Etryptamine

    go.drugbank.com/drugs/DB01546
    ApprovedIllicitWithdrawn

    αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. … In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was